FibroGen (NASDAQ:FGEN) Share Price Passes Above 50-Day Moving Average - What's Next?

FibroGen, Inc. (NASDAQ:FGEN - Get Free Report) crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.45 and traded as high as $0.61. FibroGen shares last traded at $0.57, with a volume of 1,271,728 shares changing hands.

Analyst Upgrades and Downgrades

FGEN has been the topic of several recent research reports. StockNews.com assumed coverage on shares of FibroGen in a report on Wednesday, January 1st. They issued a "hold" rating on the stock. HC Wainwright raised FibroGen to a "strong-buy" rating in a report on Tuesday, December 17th. Finally, William Blair reissued a "market perform" rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Price Performance

The business's fifty day simple moving average is $0.45 and its two-hundred day simple moving average is $0.49. The company has a market cap of $53.42 million, a PE ratio of -0.43 and a beta of 0.75.

FibroGen (NASDAQ:FGEN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same period in the previous year, the company posted ($0.52) EPS. As a group, analysts predict that FibroGen, Inc. will post -0.8 EPS for the current year.

Institutional Trading of FibroGen

Institutional investors and hedge funds have recently modified their holdings of the stock. Point72 DIFC Ltd grew its stake in FibroGen by 734.2% during the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 45,990 shares in the last quarter. Doheny Asset Management CA purchased a new position in FibroGen during the second quarter worth approximately $48,000. Franklin Street Advisors Inc. NC boosted its stake in FibroGen by 100.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company's stock worth $106,000 after buying an additional 100,000 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in FibroGen in the 2nd quarter valued at $130,000. Finally, Sei Investments Co. increased its stake in shares of FibroGen by 38.4% in the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company's stock worth $133,000 after acquiring an additional 41,442 shares during the last quarter. Hedge funds and other institutional investors own 72.71% of the company's stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.